RT Journal Article
SR Electronic
T1 Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.15.20065623
DO 10.1101/2020.04.15.20065623
A1 Xiaoli Wang
A1 Xianghua Guo
A1 Qianqian Xin
A1 Yang Pan
A1 Jing Li
A1 Yanhui Chu
A1 Yingmei Feng
A1 Quanyi Wang
YR 2020
UL http://medrxiv.org/content/early/2020/04/23/2020.04.15.20065623.abstract
AB Background COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The urgent needs for exploring the neutralizing antibodies from patients with different clinical characteristics are emerging.Methods A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. The presence of neutralizing antibody was determined with a modified cytopathogenic assay based on live SARS-CoV-2. The dynamics of neutralizing antibody levels at different with different clinical characteristics were analyzed.Results The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till day 41-53. The total GMT was 1:163.7 (95% CI, 128.5 to 208.6), and the antibody level was highest during day 31-40 since onset, and then decreased slightly. Individual differences in changes of antibody levels were observed among 8 representative convalescent patients. In multivariate GEE analysis, patients at age of 31-60 and 61-84 had a higher antibody level than those at age of 16-30 (β=1.0518, P=0.0152; β=1.3718, P=0.0020). Patients with a worse clinical classification had a higher antibody titer (β=0.4639, P=0.0227).Conclusions The neutralizing antibodies were detected even at the early stage of disease, and a significant response showed in convalescent patients. Moreover, changes on antibody levels ware individual specific.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialLL-2020-041-KFunding StatementThis study was funded by National Key Research and Development Program of China (2020YFC0842100), Beijing Science and Technology Program (Z201100005420006), and Beijing Traditional Chinese Medicine (TCM) Science and Technology Development (# BJYAYY-2020YC-02).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript were from our own testing.